Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 5

Sponsor Class

OTHER 6INDUSTRY 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Dermatologic 5CNS 2

Conditions

Carcinoma, Basal Cell 5Medulloblastoma 4Recurrence 3Basal Cell Nevus Syndrome 2Thrombocytosis 1Thrombocythemia, Essential 1Stomach Neoplasms 1Skin Neoplasms 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1

Interventions

HhAntag691 11sonidegib 5cemiplimab 5methyl 5-aminolevulinate 4daromun 4Imiquimod 3IPI-926 3gusacitinib 2Photochemotherapy 2Drug Evaluation 23-ingenyl angelate 2tozuleristide 1silmitasertib 1pembrolizumab 1TAK-441 1NVP-LEQ506 1MAPRE1 protein, human 1Intravital Microscopy 1Interleukin-2 1Injections 1IFL protocol 1Folfox protocol 1Capecitabine 1Bevacizumab 1BO-112 1BMS-833923 1BF-200 ALA 1Ascorbic Acid 1Aminolevulinic Acid 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Basal Cell × sonidegib × Clear all
NCT04066504 2026-03-18

NISSO

Sun Pharmaceutical Industries Limited

Completed
323 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00880308 2020-12-19

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
103 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01208831 2020-12-19

An East Asian Study of LDE225

Novartis

Phase 1 Completed
45 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01327053 2019-08-28

BOLT

Novartis

Phase 2 Completed
230 enrolled 26 charts
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT01350115 2015-10-19

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Novartis

Phase 2 Completed
10 enrolled 9 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡